Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1

Status

Terminated 2Recruiting 2Completed 1

Sponsor Class

OTHER 9INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 308Lung Neoplasms 70Neoplasms 50Neoplasm Metastasis 33Parkinson Disease 4, Autosomal Dominant Lewy Body 20Colorectal Neoplasms 20Carcinoma 20Mesothelioma 15Breast Neoplasms 15Mesothelioma, Malignant 13Small Cell Lung Carcinoma 11Melanoma 10Adenocarcinoma 10Neoplasms by Site 9Adenocarcinoma of Lung 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Lung Diseases 7Thoracic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Non-Squamous Non-Small Cell Lung Cancer 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Respiratory Tract Diseases 5Recurrence 5Rectal Neoplasms 5Neoplasms by Histologic Type 5NSCLC 5Head and Neck Neoplasms 5Endometrial Neoplasms 5

Interventions

Carboplatin 7aflutinib 5Pemetrexed 5osimertinib 4Gefitinib 4HM781-36B 3rezivertinib 2pembrolizumab 2Paclitaxel 2HMPL-013 2Docetaxel 2Cisplatin 2Albumin-Bound Paclitaxel 2tipifarnib 1sulindac sulfone 1spartalizumab 1icotinib 1aumolertinib 1apatinib 1Vinorelbine 1Taxes 1Gemcitabine 1Erlotinib Hydrochloride 1Clinical Trials, Phase I as Topic 1Cetuximab 1CP protocol 1Bortezomib 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × NSCLC × Pemetrexed × Clear all
NCT05636267 2026-03-09

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Akeso

Phase 1/2 Terminated
59 enrolled
Thoracic

NSCLC

NCT07181499 2025-09-30

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Betta Pharmaceuticals Co., Ltd.

Phase 2 Recruiting
28 enrolled
Thoracic

NSCLC

NCT06754644 2025-06-10

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
808 enrolled
Thoracic

NSCLC

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

NCT03562871 2022-04-21

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

IO Biotech

Phase 1/2 Completed
109 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡